442 related articles for article (PubMed ID: 33784104)
1. Drug Release and Nanodroplet Formation from Amorphous Solid Dispersions: Insight into the Roles of Drug Physicochemical Properties and Polymer Selection.
Yang R; Mann AKP; Van Duong T; Ormes JD; Okoh GA; Hermans A; Taylor LS
Mol Pharm; 2021 May; 18(5):2066-2081. PubMed ID: 33784104
[TBL] [Abstract][Full Text] [Related]
2. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
Purohit HS; Taylor LS
Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
[TBL] [Abstract][Full Text] [Related]
3. Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition.
Saboo S; Kestur US; Flaherty DP; Taylor LS
Mol Pharm; 2020 Apr; 17(4):1261-1275. PubMed ID: 32134677
[TBL] [Abstract][Full Text] [Related]
4. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
Indulkar AS; Lou X; Zhang GGZ; Taylor LS
Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
[TBL] [Abstract][Full Text] [Related]
5. Thermodynamic and kinetic evaluation of the impact of polymer excipients on storage stability of amorphous itraconazole.
Zhang S; Lee TWY; Chow AHL
Int J Pharm; 2019 Jan; 555():394-403. PubMed ID: 30513399
[TBL] [Abstract][Full Text] [Related]
6. Physical stability of API/polymer-blend amorphous solid dispersions.
Lehmkemper K; Kyeremateng SO; Bartels M; Degenhardt M; Sadowski G
Eur J Pharm Biopharm; 2018 Mar; 124():147-157. PubMed ID: 29269154
[TBL] [Abstract][Full Text] [Related]
7. Congruent release of drug and polymer: A "sweet spot" in the dissolution of amorphous solid dispersions.
Saboo S; Mugheirbi NA; Zemlyanov DY; Kestur US; Taylor LS
J Control Release; 2019 Mar; 298():68-82. PubMed ID: 30731151
[TBL] [Abstract][Full Text] [Related]
8. Interaction of Polymers with Enzalutamide Nanodroplets-Impact on Droplet Properties and Induction Times.
Wilson VR; Mugheirbi NA; Mosquera-Giraldo LI; Deac A; Moseson DE; Smith DT; Novo DC; Borca CH; Slipchenko LV; Edgar KJ; Taylor LS
Mol Pharm; 2021 Mar; 18(3):836-849. PubMed ID: 33539105
[TBL] [Abstract][Full Text] [Related]
9. Patterns of drug release as a function of drug loading from amorphous solid dispersions: A comparison of five different polymers.
Saboo S; Moseson DE; Kestur US; Taylor LS
Eur J Pharm Sci; 2020 Dec; 155():105514. PubMed ID: 32810579
[TBL] [Abstract][Full Text] [Related]
10. Impact of Polymer Type and Relative Humidity on the Long-Term Physical Stability of Amorphous Solid Dispersions.
Lehmkemper K; Kyeremateng SO; Heinzerling O; Degenhardt M; Sadowski G
Mol Pharm; 2017 Dec; 14(12):4374-4386. PubMed ID: 29050468
[TBL] [Abstract][Full Text] [Related]
11. Impact of Drug-Polymer Intermolecular Interactions on Dissolution Performance of Copovidone-Based Amorphous Solid Dispersions.
Que C; Deac A; Zemlyanov DY; Qi Q; Indulkar AS; Gao Y; Zhang GGZ; Taylor LS
Mol Pharm; 2021 Sep; 18(9):3496-3508. PubMed ID: 34319746
[TBL] [Abstract][Full Text] [Related]
12. Balancing Solid-State Stability and Dissolution Performance of Lumefantrine Amorphous Solid Dispersions: The Role of Polymer Choice and Drug-Polymer Interactions.
Hiew TN; Zemlyanov DY; Taylor LS
Mol Pharm; 2022 Feb; 19(2):392-413. PubMed ID: 34494842
[TBL] [Abstract][Full Text] [Related]
13. Origin of Nanodroplet Formation Upon Dissolution of an Amorphous Solid Dispersion: A Mechanistic Isotope Scrambling Study.
Indulkar AS; Waters JE; Mo H; Gao Y; Raina SA; Zhang GGZ; Taylor LS
J Pharm Sci; 2017 Aug; 106(8):1998-2008. PubMed ID: 28431965
[TBL] [Abstract][Full Text] [Related]
14. Insights into the Release Mechanisms of ITZ:HPMCAS Amorphous Solid Dispersions: The Role of Drug-Rich Colloids.
Nunes PD; Pinto JF; Henriques J; Paiva AM
Mol Pharm; 2022 Jan; 19(1):51-66. PubMed ID: 34919407
[TBL] [Abstract][Full Text] [Related]
15. Direct Visualization of Drug-Polymer Phase Separation in Ritonavir-Copovidone Amorphous Solid Dispersions Using
Shi C; Li L; Zhang GGZ; Borchardt TB
Mol Pharm; 2019 Nov; 16(11):4751-4754. PubMed ID: 31553871
[TBL] [Abstract][Full Text] [Related]
16. Combining crystalline and polymeric excipients in API solid dispersions - Opportunity or risk?
Veith H; Wiechert F; Luebbert C; Sadowski G
Eur J Pharm Biopharm; 2021 Jan; 158():323-335. PubMed ID: 33296719
[TBL] [Abstract][Full Text] [Related]
17. Phase behavior of pharmaceutically relevant polymer/solvent mixtures.
Dohrn S; Luebbert C; Lehmkemper K; Kyeremateng SO; Degenhardt M; Sadowski G
Int J Pharm; 2020 Mar; 577():119065. PubMed ID: 31988034
[TBL] [Abstract][Full Text] [Related]
18. Hypromellose acetate succinate based amorphous solid dispersions via hot melt extrusion: Effect of drug physicochemical properties.
Sarabu S; Kallakunta VR; Bandari S; Batra A; Bi V; Durig T; Zhang F; Repka MA
Carbohydr Polym; 2020 Apr; 233():115828. PubMed ID: 32059882
[TBL] [Abstract][Full Text] [Related]
19. Solvent influence on the phase behavior and glass transition of Amorphous Solid Dispersions.
Dohrn S; Luebbert C; Lehmkemper K; Kyeremateng SO; Degenhardt M; Sadowski G
Eur J Pharm Biopharm; 2021 Jan; 158():132-142. PubMed ID: 33212185
[TBL] [Abstract][Full Text] [Related]
20. Mutual Impact of Phase Separation/Crystallization and Water Sorption in Amorphous Solid Dispersions.
Luebbert C; Wessner M; Sadowski G
Mol Pharm; 2018 Feb; 15(2):669-678. PubMed ID: 29309155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
